Elevated	O
Serum	B:C0229671
Krebs	O
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
in	O
Early	O
Disease	O
Predicts	O
Subsequent	O
Deterioration	O
of	O
Pulmonary	O
Function	I:C0231921
in	O
Patients	O
with	O
Systemic	O
Sclerosis	I:C0036421
and	O
Interstitial	O
Lung	I:C0206062
Disease	I:C0206062
.	O

Elevated	O
Serum	O
Krebs	B:C1612111
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
in	O
Early	O
Disease	O
Predicts	O
Subsequent	O
Deterioration	O
of	O
Pulmonary	O
Function	I:C0231921
in	O
Patients	O
with	O
Systemic	O
Sclerosis	I:C0036421
and	O
Interstitial	O
Lung	I:C0206062
Disease	I:C0206062
.	O

Elevated	O
Serum	O
Krebs	O
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
in	O
Early	O
Disease	B:C0012634
Predicts	O
Subsequent	O
Deterioration	O
of	O
Pulmonary	O
Function	I:C0231921
in	O
Patients	O
with	O
Systemic	O
Sclerosis	I:C0036421
and	O
Interstitial	O
Lung	I:C0206062
Disease	I:C0206062
.	O

Elevated	O
Serum	O
Krebs	O
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
in	O
Early	O
Disease	O
Predicts	O
Subsequent	O
Deterioration	O
of	O
Pulmonary	B:C0231921
Function	I:C0231921
in	O
Patients	O
with	O
Systemic	O
Sclerosis	I:C0036421
and	O
Interstitial	O
Lung	I:C0206062
Disease	I:C0206062
.	O

Elevated	O
Serum	O
Krebs	O
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
in	O
Early	O
Disease	O
Predicts	O
Subsequent	O
Deterioration	O
of	O
Pulmonary	O
Function	I:C0231921
in	O
Patients	O
with	O
Systemic	B:C0036421
Sclerosis	I:C0036421
and	O
Interstitial	O
Lung	I:C0206062
Disease	I:C0206062
.	O

Elevated	O
Serum	O
Krebs	O
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
in	O
Early	O
Disease	O
Predicts	O
Subsequent	O
Deterioration	O
of	O
Pulmonary	O
Function	I:C0231921
in	O
Patients	O
with	O
Systemic	O
Sclerosis	I:C0036421
and	O
Interstitial	B:C0206062
Lung	I:C0206062
Disease	I:C0206062
.	O

To	O
identify	O
predictors	O
of	O
poor	O
prognosis	B:C0033325
in	O
patients	O
with	O
systemic	O
sclerosis	I:C0036421
(	O
systemic	O
sclerosis	I:C0036421
)	O
associated	O
with	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
(	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
)	O
.	O

To	O
identify	O
predictors	O
of	O
poor	O
prognosis	O
in	O
patients	O
with	O
systemic	B:C0036421
sclerosis	I:C0036421
(	O
systemic	O
sclerosis	I:C0036421
)	O
associated	O
with	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
(	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
)	O
.	O

To	O
identify	O
predictors	O
of	O
poor	O
prognosis	O
in	O
patients	O
with	O
systemic	O
sclerosis	I:C0036421
(	O
systemic	B:C0036421
sclerosis	I:C0036421
)	O
associated	O
with	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
(	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
)	O
.	O

To	O
identify	O
predictors	O
of	O
poor	O
prognosis	O
in	O
patients	O
with	O
systemic	O
sclerosis	I:C0036421
(	O
systemic	O
sclerosis	I:C0036421
)	O
associated	O
with	O
interstitial	B:C0206062
lung	I:C0206062
disease	I:C0206062
(	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
)	O
.	O

To	O
identify	O
predictors	O
of	O
poor	O
prognosis	O
in	O
patients	O
with	O
systemic	O
sclerosis	I:C0036421
(	O
systemic	O
sclerosis	I:C0036421
)	O
associated	O
with	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
(	O
interstitial	B:C0206062
lung	I:C0206062
disease	I:C0206062
)	O
.	O

Fifty	O
patients	O
with	O
early	O
-	O
stage	O
systemic	B:C0036421
sclerosis	I:C0036421
-	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
who	O
had	O
never	O
received	O
disease	O
-	O
modifying	O
drugs	O
and	O
were	O
either	O
observed	O
for	O
≥	O
10	O
years	O
or	O
died	O
from	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
-	O
related	O
causes	O
were	O
enrolled	O
.	O

Fifty	O
patients	O
with	O
early	O
-	O
stage	O
systemic	O
sclerosis	I:C0036421
-	O
interstitial	B:C0206062
lung	I:C0206062
disease	I:C0206062
who	O
had	O
never	O
received	O
disease	O
-	O
modifying	O
drugs	O
and	O
were	O
either	O
observed	O
for	O
≥	O
10	O
years	O
or	O
died	O
from	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
-	O
related	O
causes	O
were	O
enrolled	O
.	O

Fifty	O
patients	O
with	O
early	O
-	O
stage	O
systemic	O
sclerosis	I:C0036421
-	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
who	O
had	O
never	O
received	O
disease	B:C0012634
-	O
modifying	O
drugs	O
and	O
were	O
either	O
observed	O
for	O
≥	O
10	O
years	O
or	O
died	O
from	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
-	O
related	O
causes	O
were	O
enrolled	O
.	O

Fifty	O
patients	O
with	O
early	O
-	O
stage	O
systemic	O
sclerosis	I:C0036421
-	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
who	O
had	O
never	O
received	O
disease	O
-	O
modifying	O
drugs	B:C0013227
and	O
were	O
either	O
observed	O
for	O
≥	O
10	O
years	O
or	O
died	O
from	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
-	O
related	O
causes	O
were	O
enrolled	O
.	O

Fifty	O
patients	O
with	O
early	O
-	O
stage	O
systemic	O
sclerosis	I:C0036421
-	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
who	O
had	O
never	O
received	O
disease	O
-	O
modifying	O
drugs	O
and	O
were	O
either	O
observed	O
for	O
≥	O
10	O
years	O
or	O
died	B:C0011065
from	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
-	O
related	O
causes	O
were	O
enrolled	O
.	O

Fifty	O
patients	O
with	O
early	O
-	O
stage	O
systemic	O
sclerosis	I:C0036421
-	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
who	O
had	O
never	O
received	O
disease	O
-	O
modifying	O
drugs	O
and	O
were	O
either	O
observed	O
for	O
≥	O
10	O
years	O
or	O
died	O
from	O
interstitial	B:C0206062
lung	I:C0206062
disease	I:C0206062
-	O
related	O
causes	O
were	O
enrolled	O
.	O

Fifty	O
patients	O
with	O
early	O
-	O
stage	O
systemic	O
sclerosis	I:C0036421
-	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
who	O
had	O
never	O
received	O
disease	O
-	O
modifying	O
drugs	O
and	O
were	O
either	O
observed	O
for	O
≥	O
10	O
years	O
or	O
died	O
from	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
-	O
related	O
causes	B:C0007465
were	O
enrolled	O
.	O

The	O
baseline	O
variables	O
of	O
patients	O
who	O
developed	O
endstage	B:C0024115
lung	I:C0024115
disease	I:C0024115
(	O
endstage	O
lung	I:C0024115
disease	I:C0024115
)	O
were	O
compared	O
with	O
those	O
of	O
patients	O
who	O
remained	O
endstage	O
lung	I:C0024115
disease	I:C0024115
-	O
free	O
,	O
and	O
the	O
Cox	O
proportional	I:C0033489
hazard	I:C0033489
model	I:C0033489
was	O
used	O
to	O
identify	O
initial	O
factors	O
that	O
correlated	O
with	O
endstage	O
lung	I:C0024115
disease	I:C0024115
development	O
.	O

The	O
baseline	O
variables	O
of	O
patients	O
who	O
developed	O
endstage	O
lung	I:C0024115
disease	I:C0024115
(	O
endstage	B:C0024115
lung	I:C0024115
disease	I:C0024115
)	O
were	O
compared	O
with	O
those	O
of	O
patients	O
who	O
remained	O
endstage	O
lung	I:C0024115
disease	I:C0024115
-	O
free	O
,	O
and	O
the	O
Cox	O
proportional	I:C0033489
hazard	I:C0033489
model	I:C0033489
was	O
used	O
to	O
identify	O
initial	O
factors	O
that	O
correlated	O
with	O
endstage	O
lung	I:C0024115
disease	I:C0024115
development	O
.	O

The	O
baseline	O
variables	O
of	O
patients	O
who	O
developed	O
endstage	O
lung	I:C0024115
disease	I:C0024115
(	O
endstage	O
lung	I:C0024115
disease	I:C0024115
)	O
were	O
compared	O
with	O
those	O
of	O
patients	O
who	O
remained	O
endstage	B:C0024115
lung	I:C0024115
disease	I:C0024115
-	O
free	O
,	O
and	O
the	O
Cox	O
proportional	I:C0033489
hazard	I:C0033489
model	I:C0033489
was	O
used	O
to	O
identify	O
initial	O
factors	O
that	O
correlated	O
with	O
endstage	O
lung	I:C0024115
disease	I:C0024115
development	O
.	O

The	O
baseline	O
variables	O
of	O
patients	O
who	O
developed	O
endstage	O
lung	I:C0024115
disease	I:C0024115
(	O
endstage	O
lung	I:C0024115
disease	I:C0024115
)	O
were	O
compared	O
with	O
those	O
of	O
patients	O
who	O
remained	O
endstage	O
lung	I:C0024115
disease	I:C0024115
-	O
free	O
,	O
and	O
the	O
Cox	B:C0033489
proportional	I:C0033489
hazard	I:C0033489
model	I:C0033489
was	O
used	O
to	O
identify	O
initial	O
factors	O
that	O
correlated	O
with	O
endstage	O
lung	I:C0024115
disease	I:C0024115
development	O
.	O

The	O
baseline	O
variables	O
of	O
patients	O
who	O
developed	O
endstage	O
lung	I:C0024115
disease	I:C0024115
(	O
endstage	O
lung	I:C0024115
disease	I:C0024115
)	O
were	O
compared	O
with	O
those	O
of	O
patients	O
who	O
remained	O
endstage	O
lung	I:C0024115
disease	I:C0024115
-	O
free	O
,	O
and	O
the	O
Cox	O
proportional	I:C0033489
hazard	I:C0033489
model	I:C0033489
was	O
used	O
to	O
identify	O
initial	O
factors	O
that	O
correlated	O
with	O
endstage	B:C0024115
lung	I:C0024115
disease	I:C0024115
development	O
.	O

Sixteen	O
patients	O
(	O
32	O
%	O
)	O
developed	O
endstage	B:C0024115
lung	I:C0024115
disease	I:C0024115
during	O
173.5	O
±	O
64.7	O
months	O
of	O
followup	O
.	O

Sixteen	O
patients	O
(	O
32	O
%	O
)	O
developed	O
endstage	O
lung	I:C0024115
disease	I:C0024115
during	O
173.5	O
±	O
64.7	O
months	O
of	O
followup	B:C1522577
.	O

Elevated	O
serum	B:C0229671
Krebs	O
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
(	O
KL	O
-	I:C1612111
6	I:C1612111
)	O
at	O
initial	O
assessment	O
was	O
highly	O
correlated	O
with	O
endstage	O
lung	I:C0024115
disease	I:C0024115
development	O
(	O
p	O
=	O
0.0002	O
)	O
.	O

Elevated	O
serum	O
Krebs	B:C1612111
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
(	O
KL	O
-	I:C1612111
6	I:C1612111
)	O
at	O
initial	O
assessment	O
was	O
highly	O
correlated	O
with	O
endstage	O
lung	I:C0024115
disease	I:C0024115
development	O
(	O
p	O
=	O
0.0002	O
)	O
.	O

Elevated	O
serum	O
Krebs	O
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
(	O
KL	B:C1612111
-	I:C1612111
6	I:C1612111
)	O
at	O
initial	O
assessment	O
was	O
highly	O
correlated	O
with	O
endstage	O
lung	I:C0024115
disease	I:C0024115
development	O
(	O
p	O
=	O
0.0002	O
)	O
.	O

Elevated	O
serum	O
Krebs	O
von	I:C1612111
den	I:C1612111
Lungen	I:C1612111
-	I:C1612111
6	I:C1612111
(	O
KL	O
-	I:C1612111
6	I:C1612111
)	O
at	O
initial	O
assessment	O
was	O
highly	O
correlated	O
with	O
endstage	B:C0024115
lung	I:C0024115
disease	I:C0024115
development	O
(	O
p	O
=	O
0.0002	O
)	O
.	O

Receiver	B:C0936012
-	I:C0936012
operating	I:C0936012
characteristic	I:C0936012
curve	I:C0936012
analysis	I:C0936012
revealed	O
that	O
a	O
KL	O
-	I:C1612111
6	I:C1612111
value	O
of	O
1273	O
U/	O
ml	O
effectively	O
discriminated	O
patients	O
who	O
developed	O
endstage	O
lung	I:C0024115
disease	I:C0024115
from	O
those	O
who	O
did	O
not	O
.	O

Receiver	O
-	I:C0936012
operating	I:C0936012
characteristic	I:C0936012
curve	I:C0936012
analysis	I:C0936012
revealed	O
that	O
a	O
KL	B:C1612111
-	I:C1612111
6	I:C1612111
value	O
of	O
1273	O
U/	O
ml	O
effectively	O
discriminated	O
patients	O
who	O
developed	O
endstage	O
lung	I:C0024115
disease	I:C0024115
from	O
those	O
who	O
did	O
not	O
.	O

Receiver	O
-	I:C0936012
operating	I:C0936012
characteristic	I:C0936012
curve	I:C0936012
analysis	I:C0936012
revealed	O
that	O
a	O
KL	O
-	I:C1612111
6	I:C1612111
value	O
of	O
1273	O
U/	O
ml	O
effectively	O
discriminated	O
patients	O
who	O
developed	O
endstage	B:C0024115
lung	I:C0024115
disease	I:C0024115
from	O
those	O
who	O
did	O
not	O
.	O

Patients	O
with	O
KL	B:C1612111
-	I:C1612111
6	I:C1612111
>	O
1273	O
U/	O
ml	O
were	O
less	O
likely	O
to	O
remain	O
endstage	O
lung	I:C0024115
disease	I:C0024115
-	O
free	O
compared	O
with	O
those	O
with	O
lower	O
KL	O
-	I:C1612111
6	I:C1612111
levels	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Patients	O
with	O
KL	O
-	I:C1612111
6	I:C1612111
>	O
1273	O
U/	O
ml	O
were	O
less	O
likely	O
to	O
remain	O
endstage	B:C0024115
lung	I:C0024115
disease	I:C0024115
-	O
free	O
compared	O
with	O
those	O
with	O
lower	O
KL	O
-	I:C1612111
6	I:C1612111
levels	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Patients	O
with	O
KL	O
-	I:C1612111
6	I:C1612111
>	O
1273	O
U/	O
ml	O
were	O
less	O
likely	O
to	O
remain	O
endstage	O
lung	I:C0024115
disease	I:C0024115
-	O
free	O
compared	O
with	O
those	O
with	O
lower	O
KL	B:C1612111
-	I:C1612111
6	I:C1612111
levels	O
(	O
p	O
<	O
0.0001	O
)	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
KL	B:C1612111
-	I:C1612111
6	I:C1612111
>	O
1273	O
U/ml	O
was	O
the	O
most	O
reliable	O
predictor	O
of	O
endstage	O
lung	I:C0024115
disease	I:C0024115
development	O
(	O
OR	O
51.2	O
,	O
95	O
%	O
CI	O
7.6-343	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
KL	O
-	I:C1612111
6	I:C1612111
>	O
1273	O
U/ml	O
was	O
the	O
most	O
reliable	O
predictor	O
of	O
endstage	B:C0024115
lung	I:C0024115
disease	I:C0024115
development	O
(	O
OR	O
51.2	O
,	O
95	O
%	O
CI	O
7.6-343	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Finally	O
,	O
the	O
initial	O
KL	B:C1612111
-	I:C1612111
6	I:C1612111
level	O
correlated	O
with	O
the	O
forced	O
vital	I:C0580371
capacity	I:C0580371
(	O
forced	O
vital	I:C0580371
capacity	I:C0580371
)	O
decline	O
rate	O
(	O
r	O
=	O
0.58	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Finally	O
,	O
the	O
initial	O
KL	O
-	I:C1612111
6	I:C1612111
level	O
correlated	O
with	O
the	O
forced	B:C0580371
vital	I:C0580371
capacity	I:C0580371
(	O
forced	O
vital	I:C0580371
capacity	I:C0580371
)	O
decline	O
rate	O
(	O
r	O
=	O
0.58	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

Finally	O
,	O
the	O
initial	O
KL	O
-	I:C1612111
6	I:C1612111
level	O
correlated	O
with	O
the	O
forced	O
vital	I:C0580371
capacity	I:C0580371
(	O
forced	B:C0580371
vital	I:C0580371
capacity	I:C0580371
)	O
decline	O
rate	O
(	O
r	O
=	O
0.58	O
,	O
p	O
<	O
0.0001	O
)	O
.	O

The	O
natural	O
course	O
of	O
systemic	B:C0036421
sclerosis	I:C0036421
-	O
interstitial	O
lung	I:C0206062
disease	I:C0206062
is	O
highly	O
variable	O
.	O

The	O
natural	O
course	O
of	O
systemic	O
sclerosis	I:C0036421
-	O
interstitial	B:C0206062
lung	I:C0206062
disease	I:C0206062
is	O
highly	O
variable	O
.	O

Baseline	O
serum	B:C0229671
KL	O
-	I:C1612111
6	I:C1612111
is	O
a	O
biomarker	O
potentially	O
useful	O
for	O
predicting	O
forced	O
vital	I:C0580371
capacity	I:C0580371
decline	O
.	O

Baseline	O
serum	O
KL	B:C1612111
-	I:C1612111
6	I:C1612111
is	O
a	O
biomarker	O
potentially	O
useful	O
for	O
predicting	O
forced	O
vital	I:C0580371
capacity	I:C0580371
decline	O
.	O

Baseline	O
serum	O
KL	O
-	I:C1612111
6	I:C1612111
is	O
a	O
biomarker	B:C0005516
potentially	O
useful	O
for	O
predicting	O
forced	O
vital	I:C0580371
capacity	I:C0580371
decline	O
.	O

Baseline	O
serum	O
KL	O
-	I:C1612111
6	I:C1612111
is	O
a	O
biomarker	O
potentially	O
useful	O
for	O
predicting	O
forced	B:C0580371
vital	I:C0580371
capacity	I:C0580371
decline	O
.	O

